Log in

LON:HEMOHemogenyx Pharmaceuticals Share Price, Forecast & News

GBX 8.15
+0.20 (+2.52 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
7.75
Now: GBX 8.15
8.29
50-Day Range
5.35
MA: GBX 6.92
9
52-Week Range
0.06
Now: GBX 8.15
15.25
Volume1.28 million shs
Average Volume8.01 million shs
Market Capitalization£35.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants. The company has a research collaboration agreement with The Rockefeller University to develop treatments for autoimmune diseases. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 0.11 per share
Book ValueGBX (0.10) per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£35.34 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 8.15
+0.20 (+2.52 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HEMO News and Ratings via Email

Sign-up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions

How has Hemogenyx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hemogenyx Pharmaceuticals' stock was trading at GBX 1.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HEMO stock has increased by 417.5% and is now trading at GBX 8.15.
View which stocks have been most impacted by Coronavirus
.

How were Hemogenyx Pharmaceuticals' earnings last quarter?

Hemogenyx Pharmaceuticals PLC (LON:HEMO) issued its quarterly earnings results on Thursday, April, 30th. The company reported ($0.40) earnings per share for the quarter.
View Hemogenyx Pharmaceuticals' earnings history
.

Has Hemogenyx Pharmaceuticals been receiving favorable news coverage?

Press coverage about HEMO stock has been trending very positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hemogenyx Pharmaceuticals earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Hemogenyx Pharmaceuticals
.

Who are some of Hemogenyx Pharmaceuticals' key competitors?

What other stocks do shareholders of Hemogenyx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hemogenyx Pharmaceuticals investors own include Arcturus Therapeutics (ARCT), Corbus Pharmaceuticals (CRBP), Curaleaf (CURLF), Incyte (INCY), Remark (MARK), Mirati Therapeutics (MRTX), Niu Technologies (NIU), Ovid Therapeutics (OVID), Regenxbio (RGNX) and Sarepta Therapeutics (SRPT).

Who are Hemogenyx Pharmaceuticals' key executives?

Hemogenyx Pharmaceuticals' management team includes the following people:
  • Dr. Vladislav Sandler Ph.D., Co-Founder, CEO & Director
  • Ms. Alexis M. Sandler, Co-Founder & Non-Exec. Director
  • Mr. Lawrence Pemble, Chief Operating Officer
  • Sir Marc Feldmann Ph.D., MB BS, BSc(Med) Hons, PhD, FRCPath, FRCP, F, Exec. Chairman & Chairman of Advisory Board
  • Mr. Andrew Wright, Financial Controller & Company Sec.

What is Hemogenyx Pharmaceuticals' stock symbol?

Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO."

How do I buy shares of Hemogenyx Pharmaceuticals?

Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hemogenyx Pharmaceuticals' stock price today?

One share of HEMO stock can currently be purchased for approximately GBX 8.15.

How big of a company is Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals has a market capitalization of £35.34 million.

What is Hemogenyx Pharmaceuticals' official website?

The official website for Hemogenyx Pharmaceuticals is silverfalconplc.com.

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.